253 related articles for article (PubMed ID: 29079216)
1. Macular morphology following unilateral bevacizumab injection for retinopathy of prematurity: an OCT study.
Clark A; Wright T; Isaac M; Westall C; Mireskandari K; Tehrani NN
J AAPOS; 2017 Dec; 21(6):499-501.e1. PubMed ID: 29079216
[TBL] [Abstract][Full Text] [Related]
2. Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for Type 1 Retinopathy of Prematurity.
Erol MK; Coban DT; Özdemir Ö; Tunay ZÖ; Bilgin AB; Dogan B
J Pediatr Ophthalmol Strabismus; 2015; 52(3):152-8. PubMed ID: 25859685
[TBL] [Abstract][Full Text] [Related]
3. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
4. Spectral-domain optical coherence tomography of the macula in preterm infants treated with bevacizumab for retinopathy of prematurity.
Dorta P; Kychenthal A
Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):321-6. PubMed ID: 25856817
[TBL] [Abstract][Full Text] [Related]
5. Fluorescein Angiography in Retinopathy of Prematurity: Comparison of Infants Treated with Bevacizumab to Those with Spontaneous Regression.
Mansukhani SA; Hutchinson AK; Neustein R; Schertzer J; Allen JC; Hubbard GB
Ophthalmol Retina; 2019 May; 3(5):436-443. PubMed ID: 31044736
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of intravitreal bevacizumab for zone-II retinopathy of prematurity.
Karkhaneh R; Khodabande A; Riazi-Eafahani M; Roohipoor R; Ghassemi F; Imani M; Dastjani Farahani A; Ebrahimi Adib N; Torabi H
Acta Ophthalmol; 2016 Sep; 94(6):e417-20. PubMed ID: 27009449
[TBL] [Abstract][Full Text] [Related]
7. Foveal Development in Infants Treated with Bevacizumab or Laser Photocoagulation for Retinopathy of Prematurity.
Vogel RN; Strampe M; Fagbemi OE; Visotcky A; Tarima S; Carroll J; Costakos DM
Ophthalmology; 2018 Mar; 125(3):444-452. PubMed ID: 29103792
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection.
Milani AE; Arasteh A; Saeedi-Maleki Z; Niyousha MR; Sahebazamani MA; Brumandpur F
BMC Ophthalmol; 2024 Jun; 24(1):265. PubMed ID: 38907228
[TBL] [Abstract][Full Text] [Related]
9. Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment.
Lee YS; See LC; Chang SH; Wang NK; Hwang YS; Lai CC; Chen KJ; Wu WC
Am J Ophthalmol; 2018 Aug; 192():20-30. PubMed ID: 29753851
[TBL] [Abstract][Full Text] [Related]
10. Refractive outcome of intravitreal bevacizumab injection in comparison to spontaneous regression of retinopathy of prematurity (ROP).
Etezad Razavi M; Shoeibi N; Hassanzadeh S; Kianmehr S; Bakhtiari E
Strabismus; 2020 Mar; 28(1):49-54. PubMed ID: 31790628
[No Abstract] [Full Text] [Related]
11. Intravitreal Bevacizumab for Zone II Retinopathy of Prematurity.
Larrañaga-Fragoso P; Peralta J; Bravo-Ljubetic L; Pastora N; Abelairas-Gómez J
J Pediatr Ophthalmol Strabismus; 2016 Nov; 53(6):375-382. PubMed ID: 27537247
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
Yetik H; Gunay M; Sirop S; Salihoglu Z
Graefes Arch Clin Exp Ophthalmol; 2015 Oct; 253(10):1677-83. PubMed ID: 25501298
[TBL] [Abstract][Full Text] [Related]
13. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in taiwan.
Wu WC; Yeh PT; Chen SN; Yang CM; Lai CC; Kuo HK
Ophthalmology; 2011 Jan; 118(1):176-83. PubMed ID: 20673589
[TBL] [Abstract][Full Text] [Related]
14. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
15. A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity.
Chen TA; Shields RA; Bodnar ZH; Callaway NF; Schachar IH; Moshfeghi DM
Am J Ophthalmol; 2019 Feb; 198():63-69. PubMed ID: 30312578
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
[TBL] [Abstract][Full Text] [Related]
17. A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity.
Khodabande A; Niyousha MR; Roohipoor R
J AAPOS; 2016 Dec; 20(6):490-492. PubMed ID: 27794470
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal injection of bevacizumab for retinopathy of prematurity.
Kuniyoshi K; Sugioka K; Sakuramoto H; Kusaka S; Wada N; Shimomura Y
Jpn J Ophthalmol; 2014 May; 58(3):237-43. PubMed ID: 24566819
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of intravitreal aflibercept monotherapy in retinopathy of prematurity evaluated by periodic fluorescence angiography and optical coherence tomography.
Vural A; Perente İ; Onur İU; Eriş E; Seymen Z; Hergünsel GO; Salihoğlu Ö; Yiğit FU
Int Ophthalmol; 2019 Oct; 39(10):2161-2169. PubMed ID: 30478752
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
Gunay M; Sukgen EA; Celik G; Kocluk Y
Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
